Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit latenter Tuberkulose bei Therapien mit biologischen oder „targeted synthetic“ DMARDs („disease modifying antirheumatic drugs“)

Consensus Statement 2011 Österreichische Ärztezeitung. https://infektiologie.co.at/wp-content/uploads/2017/08/cs-tbc_u_biologika.pdf. Zugegriffen: 10.10.2022 WHO-Global Tuberculosis Report 2020. https://www.who.int/publications/i/item/9789240013131. Zugegriffen: 10.10.2022 https://www.ages.at/themen/krankheitserreger/tuberkulose-tbc/. Zugegriffen: 10.10.2022 WHO (Hrsg) (2018) Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization, Geneva van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761–1766. https://doi.org/10.3899/jrheum.150051 Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE (2020) Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis 12:1759720X20930116 Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernández-Ruiz M, Salzberger B, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71–S82. https://doi.org/10.1016/j.cmi.2018.02.003 Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104. https://doi.org/10.1056/NEJMoa011110 Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Judina Bastiampillai A, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F (2016) Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 15(sup1):11–34. https://doi.org/10.1080/14740338.2016.1240783 Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor‑α agents). Clin Microbiol Infect 24(Suppl 2):S10–S20. https://doi.org/10.1016/j.cmi.2017.12.025 Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522–528 Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21–S40. https://doi.org/10.1016/j.cmi.2018.02.002 Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, Goletti D (2015) Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Autoimmun Rev 14(6):503–509. https://doi.org/10.1016/j.autrev.2015.01.011 Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015) Effectiveness and tuberculosis-related safety profile of interleukin‑1 blocking agents in the management of Behçet’s disease. Autoimmun Rev 14(1):1–9. https://doi.org/10.1016/j.autrev.2014.08.008 Cantini F, Niccoli L, Capone A, Petrone L, Goletti D (2019) Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 18(5):415–425. https://doi.org/10.1080/14740338.2019.1612872 de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J et al (2010) Revisiting human IL-12Rb1 deficiency: a survey of 141 patients from 30 countries. Medicine 89:381–402 Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A (2019) Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol 71(7):1125–1134 Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J (2017) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 31(3):507–517. https://doi.org/10.1111/jdv.14015 Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, Soung J, Bao W, Keininger D, Marfo K, Patekar M, Sharma A, Shete A, Lebwohl MG (2021) Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol 157(1):43–51. https://doi.org/10.1001/jamadermatol.2020.3257 (Erratum in: JAMA Dermatol. 2021 Jan 1;157(1):124) Ribero S, Licciardello M, Quaglino P, Dapavo P (2019) Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol 11(Suppl 1):23–28. https://doi.org/10.1159/000501989 Markle JG, Martĺnez-Barricarte RCS, Ma CS, Deenick EK, Ramírez-Alejo N, Mele F, Latorre D, Alireza Mahdaviani S, Aytekin C, Mansouri D, Bryant V, Jabot-Hanin F, Deswarte C, Nieto-Patlán A, Surace L, Kerner G, Itan Y, Jovic S, Avery DT, Wong N, Rao G, Patin E, Okada S, Bigio B, Boisson B, Rapaport F, Seeleuthner Y, Schmidt M, Ikinciogullari A, Dogu F, Tanir G, Tabarsi P, Bloursaz MRJKJ, Avneet Heer, Kong X‑F, Migaud M, Lazarov T, Geissmann F, Fleckenstein B, Lindestam Arlehamn C, Sette A, Puel A, Emile J‑F, van de Vosse E, Lluis Quintana-Murci Di Santo JP, Abel L, Boisson-Dupuis S, Bustamante J, Tangye SG, Sallusto F, Casanova J‑L (2019) Human IFN‑γ immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol 3(30):eaau6759. https://doi.org/10.1126/sciimmunol.aau6759 Nogueira M, Warren RB, Torres T (2021) Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis—time for a paradigm change. J Eur Acad Dermatol Venereol 35(4):824–834 Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H (2016) Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(6):1133–1138 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D (2020) Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 19(7):861–872 Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89. https://doi.org/10.1186/s13075-019-1866-2 Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG (2017) Safety observations with 3 years of denosumab exposure: comparison between subjects who received Denosumab during the randomized FREEDOM trial and subjects who crossed over to Denosumab during the FREEDOM extension. J Bone Miner Res 32(7):1481–1485. https://doi.org/10.1002/jbmr.3119 Torres-Ortiz A, Acharya P, Cheungpasitporn W (2019) Successful treatment of tuberculosis-associated hypercalcemia with denosumab in a patient with acute kidney injury. Ther Apher Dial 23(5):484–485 Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39(11):3261–3276. https://doi.org/10.1007/s10067-020-04948-1 Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66(5):839–851 Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599–609. https://doi.org/10.1056/NEJMoa2023386 Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26):2486–2496. https://doi.org/10.1056/NEJMoa1804092 Taneja V, Kalra P, Goel M, Khilnani GC, Saini V, Prasad GBKS, Gupta UD, Prasad KH (2020) Impact and prognosis of the expression of IFN‑α among tuberculosis patients. PLoS ONE 15(7):e235488. https://doi.org/10.1371/journal.pone.0235488 Donovan ML, Schultz TE, Duke TJ, Blumenthal A (2017) Type I Interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences. Front Immunol 27(8):1633. https://doi.org/10.3389/fimmu.2017.01633 Wang J, Hussain T, Zhang K et al (2019) Inhibition of type I interferon signaling abrogates early mycobacterium bovis infection. BMC Infect Dis 19:1031. https://doi.org/10.1186/s12879-019-4654-3 Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF (2021) Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 8(1):e464. https://doi.org/10.1136/lupus-2020-000464 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R (2020) Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC. MMWR Recomm Rep 69(1):1–11. https://doi.org/10.15585/mmwr.rr6901a1 Schaberg T et al (2017) 2Sk-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 71:325–397. https://doi.org/10.1055/s-0043-105954 Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 73(7):1108–1123. https://doi.org/10.1002/art.41752 Darzi A, Harfouche M, Arayssi T, Alemadi S, Alnaqbi KA, Badsha H, Al Balushi F, Elzorkany B, Halabi H, Hamoudeh M, Hazer W, Masri B, Omair MA, Uthman I, Ziade N, Singh JA, Christiansen R, Tugwell P, Schünemann HJ, Akl EA (2017) Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes 15(1):183. https://doi.org/10.1186/s12955-017-0754-1 (Erratum in: Health Qual Life Outcomes. 2017 Oct 26;15(1):214) Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655 Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509. https://doi.org/10.1136/annrheumdis-2013-204573 Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, Chan C, Yusuf MA, Litwic A, Smolen S, Topliffe J, Bennett S, Humphreys J, Green M, Ledingham J (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Baillieres Clin Rheumatol 58(2):e3–e42. https://doi.org/10.1093/rheumatology/key208 (Erratum in: Rheumatology (Oxford). 2019 Feb 1;58(2):372) Nast A et al (2021) Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges 19(7):1092–1117. https://doi.org/10.1111/ddg.14507_g Chee CBE, Khinmar KW, Gan SH, Barkham TM, Koh CK, Shen L, Wang YT (2010) Tuberculosis treatment effect on T‑cell interferon‑γ responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 36:355–361. https://doi.org/10.1183/09031936.00151309